Antigen-specific cytotoxicity and cell number of adoptively transferred T cells are efficiently maintained in vivo by re-stimulation with an antigen/interleukin-2 fusion protein

International Journal of Cancer

Volumn 82, Issue 4, 1999, Pages 569-573

  Kang, Bok Y ^a   Lim, Young S ^a   Chung, Su W ^a   Kim, Eui J ^a   Kim, Seung H ^a   Hwang, Seung Y ^b   Kim, Tae S ^a  

^a Chonnam National University   (South Korea)

^b Hanyang University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

HYBRID PROTEIN; OVALBUMIN; RECOMBINANT INTERLEUKIN 2; VIRUS VECTOR;

ADOPTIVE TRANSFER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BACULOVIRUS; COVALENT BOND; CYTOTOXICITY; DOSE RESPONSE; FEMALE; IMMUNIZATION; LYMPHOCYTE COUNT; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS; SURVIVAL TIME; T LYMPHOCYTE;

ANIMALS; CELL COUNT; EPITOPES; FEMALE; IMMUNOTHERAPY, ADOPTIVE; INTERLEUKIN-2; MICE; MICE, INBRED C57BL; OVALBUMIN; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES;

EID: 0032855661     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19990812)82:4<569::AID-IJC16>3.0.CO;2-M     Document Type: Article

References (24)

1. BALLIED, K. and STEWART, F.M., Adoptive immunotherapy. Curr. Opin. Oncol., 9, 579-583 (1997).
2. BOON, T. and OLD, L.J., Tumor antigens. Curr. Opin. Immunol., 9, 681-683 (1997).
3. CHEEVER, M.A., THOMPSON, D.B., KLARNET, J.P. and GREENBERG, P.D., Antigen-driven long term-cultured T cells proliferate in vivo, distribute widely, mediate specific tumor therapy, and persist long-term as functional memory T cells. J. exp. Med., 163, 1100-1112 (1986).
4. CHEN, T.T., TAO, M.H. and LEVY, R., Idiotype-cytokine fusion proteins as cancer vaccines. Relative efficacy of IL-2, IL-4, and granulocyte macrophage colony-stimulating factor. J. Immunol., 153, 4775-4787 (1994).
5. COLIGAN, J.E., KRUISBEEK, A.M., MARGULIES, D.H., SHEVACH, E.M. and STROBER, W., Current protocols in immunology, Wiley, New York (1995).
6. GILBOA, E., Immunotherapy of cancer with genetically modified tumor vaccines. Semin. Oncol., 23, 101-107 (1996).
7. GILLIES, S.D., YOUNG, D., Lo, K.M. and ROBERTS, S., Biological activity and in vivo clearance of antitumor antibody/cytokine fusion proteins. Bioconj. Chem., 4, 230-235 (1993).
8. GREENBERG, P.D. and CHEEVER, M.A., Treatment of disseminated leukemia with cyclophosphamide and immune cells: tumor immunity reflects long-term persistence of tumor specific donor cells. J. Immunol., 133, 3401-3407 (1984).
9. KAWAKAMI, Y. and ROSENBERG, S.A., Human tumor antigens recognized by T-cells. Immunol. Res., 16, 313-339 (1997).
10. KIM, T.S. and COHEN, E.P., Interleukin-2-secreting mouse fibroblasts transfected with genomic DNA from murine melanoma cells prolong the survival of mice with melanoma. Cancer Res., 54, 2531-2535 (1994).
11. KIM, T.S., DEKRUYFF, R.H., RUPPER, R., MAECKER, H.T., LEVY, S. and UMETSU, D.T., An ovalbumin-IL-12 fusion protein is more effective than ovalbumin plus free recombinant IL-12 in inducing a T helper cell type 1-dominated immune response and inhibiting antigen-specific IgE production. J. Immunol., 158, 4137-4144 (1997).
12. KIM, T.S., RUSSELL, S.J., COLLINS, M.K.L. and COHEN, E.P., Immunization with interleukin-2-secreting allogeneic mouse fibroblasts expressing melanoma-associated antigens prolongs the survival of mice with melanoma. Int. J. Cancer, 55, 865-872 (1993).
13. KIM, T.S., XU, W.S., SUN, T. and COHEN, E.P., Immunization with interleukin-2/interferon-gamma double cytokine-secreting allogeneic fibroblasts prolongs the survival of mice with melanoma. Melanoma Res., 5, 217-227 (1995).
14. KOLITZ, J.E. and MERTELSMANN, R., The immunotherapy of human cancer with interleukin 2: present status and future directions. Cancer Invest., 9, 529-542 (1991).
15. LIM, Y.S., KANG, B.Y., KIM, E.J., KIM, S.H., HWANG, S.Y. and KIM, T.S., Potentiation of antigen-specific, Th1 immune responses by multiple DNA vaccination with an ovalbumin/interferon-gamma hybrid construct. Immunology, 94, 135-141 (1998).
16. MCCARTY, T.M., LIU, X., SUN, J.Y., PERALTA, E.A., DIAMOND, D.J. and ELLENHORN, J.D., Targeting p53 for adoptive T-cell immunotherapy. Cancer Res., 58, 2601-2605 (1998).
17. NORTH, R.J., Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor dependent on elimination of tumor-induced suppressor cells. J. exp. Med., 155, 1063-1074 (1982).
18. PEACE, D.J. and CHEEVER, M.A., Toxicity and therapeutic efficacy of high-dose interleukin 2. In vivo infusion of antibody to NK-1.1 attenuates toxicity without compromising efficacy against murine leukemia. J. exp. Med., 161, 161-173 (1989).
19. PLAUTZ, G.E., BARNETT, G.H., MILLER, D.W., COHEN, B.H., PRAYSON, R.A., KRAUSS, J.C., LUCIANO, M., KANGISSER, D.B. and SHU, S., Systemic T cell adoptive immunotherapy of malignant gliomas. J. Neurosurg., 89, 42-51 (1998).
20. ROSENBERG, S.A., Keynote address: perspectives on the use of interleukin-2 in cancer treatment. Cancer J. sci. Amer., 3, S2-S6 (1997).
21. VAN ELSAS, A., SCHEIBENBOGEN, C., VAN DER MINNE, C., ZERP, S.F., KEILHOLZ, U. and SCHRIER, P.I., UV-induced N-ras mutations are T-cell targets in human melanoma. Melanoma Res., Suppl., 2, S107-S113 (1997).
22. WIEBKE, E.A., ROSENBERG, S.A. and LOTZE, M.T., Acute immunologic effects of interleukin-2 therapy in cancer patients: decreased delayed type hypersensitivity response and decreased proliferative response to soluble antigens. J. clin. Oncol., 6, 1440-1449 (1988).
23. XIANG, R., LODE, H.N., DREIER, T., GILLIES, S.D. and REISFELD, R.A., Induction of persistent tumor-protective immunity in mice cured of established colon carcinoma metastases. Cancer Res., 58, 3918-3925 (1998).
24. YEE, C., RIDDELL, S.R. and GREENBERG, P.D., Prospects for adoptive T cell therapy. Curr. Opin. Immunol., 9, 702-708 (1997).